News Headlines

  1. From Molecule To Market: Synkriom And AptaPharma Partner To Advance Pharmaceutical Innovation 6/18/2026

    Synkriom, a leader in pharmaceutical consulting, technology, and supply chain governance solutions, and AptaPharma, a premier U.S.-based contract development and manufacturing organization (CDMO), entered into a strategic partnership focused on accelerating the development, manufacturing, and commercialization of complex pharmaceutical therapies.

  2. SK pharmteco Announces A Strategic Collaboration With Orphan Therapeutics Accelerator For The Development And Manufacturing Of Therapeutic Products Targeting Rare Diseases 6/18/2026

    SK pharmteco today announced a collaboration agreement with Orphan Therapeutics Accelerator (OTXL), a non-profit biotechnology organization whose goal is to advance and improve access to treatments for rare diseases that are currently blocked from market launch, in order to support the advancement of new therapeutic programs.

  3. Recipharm Invests In U.S. Fill-Finish Infrastructure To Accelerate Biologics Development 6/17/2026

    Recipharm, a leading global contract development and manufacturing organisation (CDMO), today announced a multi-million-dollar investment in its US operations, strengthening its ability to support pharmaceutical and biotechnology companies with advanced sterile fill and finish services for biologics and advanced therapies.

  4. Four Myths About Embedded CMOs, Busted 6/17/2026

    If you’re looking for a contract manufacturer to bring your therapy to market, you’re far from alone. Demand for manufacturing services is shaping the pharma Contract Manufacturing Industry, with analysts predicting a growth rate of nearly 7% per year until 2028.

  5. Avoiding Recalls: How To Ensure Sterility In Ophthalmic Products 6/17/2026

    In the wake of several high-profile eye drop recalls, we look at the challenges of achieving sterility in ophthalmic products, the consequences of failing to do so, and how AbbVie Contract Manufacturing ensures product sterility and safety.

  6. Cosmos Health Signs 2.86 Million-Unit Contract Manufacturing Agreement With Pharmex S.A. Across Three Dermatological Products 6/17/2026

    Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that, through its wholly owned subsidiary Cana Laboratories S.A. ("Cana"), it has entered into a five-year contract manufacturing agreement with Pharmex S.A. ("Pharmex") to produce three pharmaceutical products.

  7. JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option To Develop Therapeutic Candidates For Alzheimer's Disease, Enabled By J-Brain Cargo Technology Platform 6/17/2026

    JCR Pharmaceuticals Co., Ltd., a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced that Acumen Pharmaceuticals, Inc. exercised its exclusive option to develop, manufacture, and commercialize, on a global basis, up to two candidates for development in the treatment of Alzheimer’s disease (AD), enabled by JCR’s proprietary blood-brain barrier (BBB)-penetrating technology platform, J-Brain Cargo.

  8. Matica Biotechnology And Cirsium Biosciences Announce Adoption Of Matica Open Access Platform To Accelerate Flexible AAV Manufacturing 6/16/2026

    **Matica Biotechnology, Inc. (Matica Bio), a leading contract development and manufacturing organization (CDMO) specializing in viral vector production, and Cirsium Biosciences ("Cirsium"), a biotechnology company leveraging novel plant science to reimagine AAV manufacturing, today announced that Cirsium has joined the Matica Open Access Platform to enable greater flexibility, transparency, and scalability in AAV development and manufacturing.

  9. Fujifilm And HORIBA Co-Develop High-Sensitivity Inline Raman Measurement System For Real-Time Monitoring Of Cell Culture And Purification In Biopharmaceutical Manufacturing 6/16/2026

    FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) and HORIBA, Ltd. (President: Masayuki Adachi) today announced the co-development of a high-sensitivity inline Raman measurement system*1 that enables continuous, real-time monitoring of component concentrations directly from bioreactor and process equipment during cell culture and purification in biopharmaceutical manufacturing.

  10. Alvotech Announces FDA Acceptance Of Biologics License Application For AVT16, A Proposed Interchangeable Biosimilar To Entyvio® 6/16/2026

    Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT16, a proposed interchangeable biosimilar to Entyvio® (vedolizumab) lyophilized vial for intravenous administration.